Exclusive: U.S. opens criminal probe into alleged lapses at Eli Lilly plant - sources
By Marisa Taylor, Mike Spector and Dan Levine
Reuters
(Reuters) - The U.S. Justice Department has launched a criminal investigation into Eli Lilly and Co focused on alleged manufacturing irregularities and records tampering at a factory in Branchburg, New Jersey, that produces the pharmaceutical giant s COVID-19 therapy and other drugs, three people familiar with the matter said.
The probe represents a significant escalation of the government scrutiny on Lilly. The pharmaceutical company, one of the world s largest, has been under examination for more than a year by the U.S. Food and Drug Administration over alleged manufacturing and records violations at the Branchburg factory.
Exclusive: U S opens criminal probe into alleged lapses at Eli Lilly plant - sources
reuters.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from reuters.com Daily Mail and Mail on Sunday newspapers.
Healthcare & PharmaceuticalsEXCLUSIVE Lilly hit by staff accusations, FDA scrutiny at COVID drug factories
Marisa TaylorDan Levine
9 minute read
An Eli Lilly and Company pharmaceutical manufacturing plant is pictured at 50 ImClone Drive in Branchburg, New Jersey, March 5, 2021. REUTERS/Mike Segar
Eli Lilly & Co (LLY.N) employees have accused a factory executive of altering documents required by government regulators in an effort to downplay serious quality control problems at the U.S. plant producing the drugmakerâs COVID-19 treatment, according to an internal Lilly complaint and a source familiar with the matter.
The unsigned report, filed April 8 in Lillyâs confidential employee complaint system and reviewed by Reuters, is the latest sign of manufacturing problems at the drug giant. The complaint asserts that the executive, a top quality official at the companyâs factory in Branchburg, New Jersey, rewrote findings by Lilly technical experts at the plant, which
Exclusive: Lilly hit by staff accusations, FDA scrutiny at COVID drug factories Reuters 3 hrs ago By Dan Levine and Marisa Taylor © Reuters/MIKE SEGAR FILE PHOTO: FILE PHOTO: FILE PHOTO: An Eli Lilly and Co pharmaceutical manufacturing plant is pictured in Branchburg, New Jersey
By Dan Levine and Marisa Taylor
Popular Searches
(Reuters) - Eli Lilly & Co employees have accused a factory executive of altering documents required by government regulators in an effort to downplay serious quality control problems at the U.S. plant producing the drugmaker’s COVID-19 treatment, according to an internal Lilly complaint and a source familiar with the matter.
RPT-EXCLUSIVE-Lilly hit by staff accusations, FDA scrutiny at COVID drug factories Reuters 3 hrs ago
(Repeats to additional subscribers with no changes to the text)
By Dan Levine and Marisa Taylor
May 5 (Reuters) - Eli Lilly & Co employees have accused a factory executive of altering documents required by government regulators in an effort to downplay serious quality control problems at the U.S. plant producing the drugmaker’s COVID-19 treatment, according to an internal Lilly complaint and a source familiar with the matter.
The unsigned report, filed April 8 in Lilly’s confidential employee complaint system and reviewed by Reuters, is the latest sign of manufacturing problems at the drug giant. The complaint asserts that the executive, a top quality official at the company’s factory in Branchburg, New Jersey, rewrote findings by Lilly technical experts at the plant, which has been under investigation by the U.S. Food and Drug Administration, to make the conclusions app
vimarsana © 2020. All Rights Reserved.